Fig. 2.
pGlcNAc treatment stimulates MAPK and Ets1 expression. a Western blot analysis of total protein isolated from serum-starved EC (SS) treated with VEGF (V, 20 ng/ml) or pGlcNAc (NAG,10 μg/ml) for 15 min. Blots were probed with antibodies against phosphorylated Erk1 and Erk2 (P-Erk1/2). Blots were reprobed with antibodies against total Erk1 and Erk2. b Semiquantitative RT-PCR of total RNA isolated from serum-starved EC (SS) treated with or without VEGF (V) or pGlcNAc (NAG, 10 μg/ml) for 3 h. Primers were directed against Ets1, metallothionein 2A (MT) and S26 as an internal control. c QPCR of total RNA as described in b and assessed for Ets1 expression. d Western blot analysis of total protein isolated from serum-starved EC (SS) treated with pGlcNAc (NAG, 5 and 10 μg/ml) for 3 h and probed using antibodies directed against Ets1 and the p85 subunit of PI3 kinase as an internal control.